Epilive ER 1000 Tablet contains Levetiracetam 1000 mg, an antiepileptic medication indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Epilive ER 1000 is formulated as an extended-release tablet to provide sustained plasma concentrations, allowing once-daily dosing and improved patient compliance. It is typically prescribed as adjunctive therapy for patients inadequately controlled on other antiepileptic drugs or as monotherapy in newly diagnosed epilepsy. The medication is well-tolerated, with common adverse effects including somnolence, dizziness, headache, and fatigue. Dose adjustments may be necessary in patients with renal impairment. Epilive ER 1000 should be used cautiously in individuals with a history of psychiatric disorders, as mood changes and behavioral symptoms have been reported. Regular monitoring of clinical response and adverse effects is recommended during therapy. Patients should be advised not to discontinue treatment abruptly to avoid increased seizure frequency. Epilive ER 1000 offers an effective and convenient option for long-term seizure management under medical supervision.